Prospective Comparison of Sperm Parameters in SCD Adult Patients Before and after a 6 Months Treatment with hydroxyurea (HU)

• Published in: Blood 2012-11, Vol.120 (21), p.242-242
• Main Authors: Bachir, Dora, Lionnet, Francois, Dautremer, Justine Gellen, Stankovic, Katia, Habibi, Anoosha, Bartolucci, Pablo, Chalas, Céline, Berthaut, Isabelle, Eustache, Florence, Ravel, Célia, Kuntsman, Jean Marie, Girot, Robert, Simon, Tabassome, Mandelbaum, Jacqueline, Galacteros, Frederic
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V120.21.242.242

Abstract 242▪▪This icon denotes a clinically relevant abstract Hydroxyurea (HU) has proved its efficacy in reducing vaso-occlusive events in patients with SCD and increasing life expectancy. However, effects on fertility in adult males represent a major issue for acceptance and adherence, as HU has been reported to impair spermatogenesis through direct cytotoxic effects and hypogonadism. There are only limited data in the literature in this field and mainly retrospective. 49 adult patients aged 20–52 years with homozygous SCD eligible for first line HU treatment were enrolled after informed consent between June 2010 and April 2012 in this prospective study: HYDREP.The main objective was to compare at Day 0 and 180 of HU treatment the semen parameters according to the WHO (1999) criteria(volume, sperm concentration, viability, forward motility and morphology ). Vaso-occlusive events and other complications, number of transfusions during the 6 months preceding and following HU initiation were recorded. Hematological, biochemical, hormonal parameters, HU dosage were recorded at Day 0, Day 90 and 180. HU was begun at 15mg/Kg dose (Platt *) and modulated following haematological tolerance and renal function. Preliminary results concern the 24/49 patients, who complete the 6 months protocol.BEFORE HU - N = 49AT 6 MONTHS HU – N=24Sperm concentration (Million/ml)99 +/− 13824 +/− 56 (p = 0,01)Normal >2014/49